semaglutide controversy Why the Ozempic Conversation Has Become Unavoidable Obesity: Disease or surrogate marker?

Answer: Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications that includes semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Zepbound, Mounjaro), liraglutide (Victoza, Saxenda), and orforglipron (Foundayo), have become increasingly popular for obesity treatment (Mehrtash, JAMA Intern Med 2025)

The GLP-1 receptor activation enhances glucose-stimulated insulin secretion, slows gastric emptying , and promotes satiety

This guide compares the clinical evidence on side effects across the main GLP-1 options available in the UK

But as its popularity surges, so does the controversy surrounding it